Product Information

TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE) is a generic product labeled by Biocon Pharma Inc., priced at $0.1667 per EA under NDC 70377001511. Its NADAC has been published 300 times since Feb 24, 2021.

FDA first approved this application on Nov 10, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE)

Tacrolimus
$0.1667per EA

Strength

1 mg/1

Manufacturer

Biocon Pharma Inc.

NDC

70377001511

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

TACROLIMUS

Approval Type

Generic (ANDA)

FDA Application

ANDA212297

FDA Approved

11/10/2020

TE Code

AB

On Market Since

12/23/2020

Pharmacological Classes

Price Statistics

The NADAC for TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE) has been published 300 times since Feb 24, 2021, and over the history we have for it it has declined 70.6%. The table below summarizes its recorded NADAC range and movement.

Current price$0.1667 per EA
All-time high$0.5664 (Mar 10, 2021)
All-time low$0.1513 (Jul 22, 2026)
52-week high$0.1715
52-week low$0.1513
Median price$0.2056
Average price$0.2567
Largest weekly change-19.7% (Dec 22, 2021)
Weeks tracked300
Tracking sinceFeb 24, 2021

Price History

1W

+4.3%

1M

+8.6%

3M

+9.8%

6M

+3.3%

1Y

-2.8%

3Y

-18.6%

5Y

-60.2%

All

-70.6%

Generic Alternatives

The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE)?

The current National Average Drug Acquisition Cost (NADAC) for TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE), manufactured by Biocon Pharma Inc., is $0.1667 per EA (NDC 70377001511), effective Nov 18, 2026.

How has the price of TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE) changed over time?

Over the history we have for it, the NADAC for TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE) has declined 70.6%. It has been tracked across 300 weekly CMS publications since Feb 24, 2021.

What are the highest and lowest recorded NADAC prices for TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE)?

Since Feb 24, 2021, the NADAC for TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE) has ranged from a low of $0.1513 (Jul 22, 2026) to a high of $0.5664 (Mar 10, 2021), with a median of $0.2056 per EA.

Are there cheaper alternatives to TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE)?

Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE), is $0.1613 per EA — about 3% below TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE).

Who manufactures TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE)?

TACROLIMUS 1 MG CAPSULE (IMMEDIATE RELEASE) (NDC 70377001511) is labeled by Biocon Pharma Inc., and CMS classifies it as a generic product.